In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.

@article{Stearne2001InVE,
  title={In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.},
  author={Lorna E T Stearne and Inge C. Gyssens and Wil H. F. Goessens and Johan W Mouton and Wim J. G. Oyen and Jos W M van der Meer and Henri A. Verbrugh},
  journal={Antimicrobial agents and chemotherapy},
  year={2001},
  volume={45 5},
  pages={1394-401}
}
The pharmacodynamic and pharmacokinetic properties of trovafloxacin were studied in a standardized murine model of established subcutaneous abscesses. Daily dosing regimens of 37.5 to 300 mg/kg every 8 h (q8h) or every 24 h (q24h) were started 3 days after inoculation with mixtures containing either Bacteroides fragilis-Escherichia coli-autoclaved cecal contents (ACC) or B. fragilis-vancomycin-resistant Enterococcus faecium (VREF)-ACC. Treatment was continued for 3 or 5 days. The efficacy of… CONTINUE READING
7 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…